Want to see ANEB full AI Analyst Report?
Anebulo Pharmaceuticals (ANEB) Ratios
Anebulo Pharmaceuticals Ratios
ANEB's free cash flow for Q2 2026 was $-1.31M. For the 2026 fiscal year, ANEB's free cash flow was increased by $0.00 and operating cash flow was $-1.31M. See a summary of the company’s cash flow.
| Ratios | Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 53.36 | 13.46 | 10.92 | 30.40 | 89.61 |
| Quick Ratio | 53.36 | 13.46 | 10.92 | 30.40 | 89.61 |
| Cash Ratio | 51.87 | 11.87 | 10.52 | 28.39 | 82.71 |
| Solvency Ratio | -16.61 | -30.48 | -10.98 | -13.32 | -125.20 |
| Operating Cash Flow Ratio | -28.32 | -31.05 | -9.06 | -10.61 | -20.16 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 11.47M | $ 3.25M | $ 10.60M | $ 15.07M | $ 21.41M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.04 | 1.07 | 1.10 | 1.03 | 1.01 |
| Debt Service Coverage Ratio | -20.21 | -51.52 | 0.00 | 0.00 | -2569.98 |
| Interest Coverage Ratio | -24.14 | -54.94 | 0.00 | 0.00 | -307.13 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 1.51 | 0.40 | 0.96 | 2.13 | 0.66 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 91.99% | 98.71% | 99.56% | 99.92% | 837.11% |
| Return on Assets (ROA) | -69.86% | -201.37% | -100.53% | -43.81% | -139.71% |
| Return on Equity (ROE) | -72.78% | -215.13% | -110.67% | -45.30% | -141.29% |
| Return on Capital Employed (ROCE) | -77.37% | -217.94% | -111.15% | -45.34% | -16.88% |
| Return on Invested Capital (ROIC) | -77.37% | -217.94% | -111.15% | -45.34% | -16.88% |
| Return on Tangible Assets | -69.86% | -201.37% | -100.53% | -43.81% | -139.71% |
| Earnings Yield | -17.42% | -11.85% | -19.91% | -5.62% | -19.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.19 | -0.31 | -0.39 | -0.23 | -0.21 |
| Free Cash Flow Per Share | -0.19 | -0.31 | -0.39 | -0.23 | -0.21 |
| Dividend Paid and CapEx Coverage Ratio | -2116562.33 | -8090849.00 | 0.00 | -1359293.50 | 0.00 |
| Capital Expenditure Coverage Ratio | -2116562.33 | -8090849.00 | 0.00 | -1359293.50 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -13.04% | -11.69% | -16.43% | -4.48% | -3.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.76 | -8.44 | -5.02 | -17.79 | -5.26 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.18 | 18.15 | 5.56 | 8.06 | 7.44 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.67 | -8.55 | -6.09 | -22.33 | -32.68 |
| Price-to-Operating Cash Flow Ratio | -7.67 | -8.55 | -6.09 | -22.33 | -32.68 |
| Price-to-Earnings Growth (PEG) Ratio | 0.26 | 0.26 | -0.08 | 0.23 | -0.00 |
| Enterprise Value Multiple | -4.80 | -8.48 | -4.06 | -15.65 | -4.60 |
| Enterprise Value | 37.07M | 66.11M | 47.68M | 106.85M | 139.23M |
| EV to EBITDA | -4.80 | -8.48 | -4.06 | -15.65 | -4.60 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -5.84 | -8.17 | -4.92 | -19.65 | -28.58 |
| EV to Operating Cash Flow | -5.84 | -8.17 | -4.92 | -19.65 | -28.58 |
| Tangible Book Value Per Share | 0.34 | 0.15 | 0.42 | 0.65 | 0.92 |
| Shareholders’ Equity Per Share | 0.34 | 0.15 | 0.42 | 0.65 | 0.92 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.25 | -0.32 | -0.47 | -0.29 | -1.30 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.05 | 1.02 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.75 | 0.99 | 0.83 | 0.80 | 0.16 |
Currency in USD